...Teva Pharmaceutical Industries, Ltd 1) External Environment: The Pharmaceutical Industry is dependent on political and legal conditions of general environment. In pharmaceutical industry we have two kind of medications which are generic or innovative. Innovative pharmaceutical industry success depends on the patent protection in the industry. For example, in United States innovative industry can have 10 to 12 years of patent protection life from the time that product is for sale in the market. Success of the generic pharmaceuticals which are bioequivalent to innovative pharmaceutical is also related to the political and legal environment of their market. If we look at pharmaceutical industry globally we can see that regulations toward generic pharmaceutical are different in different countries. For example, in United States they have the Hatch-Waxman ACT 1984including Abbreviated New Drug Application which reduce the drugs approval period and give the chance to Generic companies to have a 180 day exclusivity period if the generic company can submit an abbreviated new drug application before other generic competitors. In Europe regulations are different in each country for example, United Kingdom and the Netherlands are very similar to USA, and countries such as Germany and France are more physician-driven or branded generics market and the cost of sale for generic products are higher in these countries. Market for generic drugs in the rest of...
Words: 1493 - Pages: 6
...9-707-441 REV: MARCH 30, 2010 TARUN KHANNA KRISHNA PALEPU CLAUDINE MADRAS Teva Pharmaceutical Industries, Ltd In Israel we have a 1970s song based on a poem from 1953 by Amir Gilboa about Theodor Herzl.1 It has a line in it about Herzl: “Suddenly a man rises in the morning, feels he is a people, and starts walking.” That is exactly what Hurvitz did. Suddenly he woke up in the morning, feels he is a giant world class company, and starts walking. No one, aside from Herzl, has accomplished anything as remotely as impressive in this country as Hurvitz. It was impossible, a million to one odds at best, and he still did it. He woke up one morning and started walking. — Ori Hershkovitz, equity analyst at Tel Aviv-based Leader & Company The markets had not been kind to Teva Pharmaceutical during the first half of 2006. The stock had plunged nearly 30% from January 1 to June 30, erasing billions of dollars from the company’s market capitalization. Even good news, such as reports in July of Teva’s wildly successful introduction of generic Zocor—the largest blockbuster drug ever to go off-patent—had failed to boost the stock significantly. Since nearly every retirement fund and mutual fund in Israel invested in Teva, this drop had been felt throughout the population, in effect amounting to every Israeli family losing NIS 3000, or $675.1 Teva was more than the world’s leading producer of generic pharmaceuticals (see Exhibit 1 for financials). It represented the gold standard of business...
Words: 12524 - Pages: 51
...Case Study TEVA Strengthens Security for Software Assets with MKS Integrity “One of the main measures for success in the implementation of the MKS Integrity Suite was the reduction in the amount of paper and forms that get manually pushed from person to person. By simply automating service request forms and routing them via electronic workflows we have become much more effective, and dramatically reduced our time spent managing projects.” Tom Loane, Chief Information Officer , TEVA Pharmaceuticals Company Overview TEVA USA is a wholly-owned subsidiary of TEVA Pharmaceutical Industries Ltd., Israel’s largest pharmaceutical manufacturer operating globally in 30 countries on 5 continents. TEVA is among the top 20 pharmaceutical companies and the largest generic pharmaceutical companies in the world. The company has approximately 14,000 employees worldwide with production facilities in Israel, North America, Europe and Mexico. TEVA USA has an aggressive Research & Development effort and one of the best overall ANDA approval records in the industry. The company’s mission is to play a leading role in the transformation of the U.S. healthcare system through its preeminence in the development, manufacturing and marketing of pharmaceuticals. The Challenge As a pharmaceutical company operating in the U.S., TEVA must comply with Food and Drug Administration (FDA) regulations. The FDA requires stringent application development and change control practices surrounding software...
Words: 1059 - Pages: 5
...Running Head: Decisions in Paradise Part II Decisions in Paradise Part II NAME MGT 350 January 23, 2012 Introduction Within the context of Decisions in Paradise I, I discussed some of the different obstacles that TEVA, USA is encountering while trying to enter the country of Kava, a South Pacific Island. I also shared different approaches that my company TEVA, USA can take to address the many challenges that the island presents. Any solution that I, or my partners, propose will have an effect on Kava and this should be taken into consideration when implementing our techniques. The process of assessing the available solutions will be explored within Decisions in Paradise II. The most difficult problem to overcome is that Kava is a hard island to inhabit because of the unavoidable issues the face with disasters and disease. In addition to the mess that the island is in, the office that TEVA occupies is also in havoc. They lack sufficient employees and the office in unorganized. After identifying the problems at hand, I have determined that the basic solutions would be; hire a new receptionist, clean up the office space, and implementing contingency plans for every natural disaster that may impact the land. This would include a safety plan, a cleaning plan, and a safe place for everyone to go when disasters do strike. Decision-making Technique Several influences have been identified to lead to the issues that are affecting Kava today. The main...
Words: 887 - Pages: 4
...the island to analyze the possibility of the plans of the Teva Pharmaceuticals to increase its presence in the island. Determining Factors Affecting the Decision Implementation The disaster threats relative to the geographic location of Kava pose considerable risks to any business operating in the island. Teva Pharmaceuticals will not be exempted from that. The threats also pose real danger to the health of the people of Kava. The risks from the disaster threats could significantly affect the health of the population particularly if accessibility to affordable health and medical supplies is difficult. The threats from AIDS/HIV alone could be devastating but the threat could be eased with available protective device such as affordable and easy accessible condom sheaths. The situation in Kava could be a great opportunity for the Teva Pharmaceuticals to expand its mission which is “to play a leading role in the transformation of the U.S. healthcare system through its pre-eminence in the development, manufacture and marketing of generic pharmaceuticals (TEVA USA., 2010, para 2)”. The company can expand that mission to the healthcare system of Kava Island highly vulnerable to many threats particularly storm, tsunami, earthquake, flood, fire, petroleum spills, AIDS/HIV, and avian flu (University of Phoenix, 2010). The condition of Kava may not be highly favorable but the island also has some benefits to offer to Teva...
Words: 1991 - Pages: 8
...PRESCRIPTION SAVINGS CARD First NUVIGIL Prescription FREE* Refills as low as $5* FOR PHARMACISTS First Prescription is FREE* On the first fill, your patient will receive up to 30 NUVIGIL tablets at no cost, subject to terms and limitations. FOR PATIENTS Refills as low as $5* On all future NUVIGIL fills, your patient’s out-of-pocket expense will be as low as $5 for each prescription refill with a maximum savings of up to $50 per prescription. INSURED PATIENT BILLING Submit a primary claim to your patient’s insurance, and then submit a secondary coordination of benefits (COB) claim to AlphaScrip. BIN: 610600 PCN: AS Group and ID numbers: located on the card PRIOR AUTHORIZATION If your insured patient’s insurance provider denied the primary claim due to a Prior Authorization (PA) requirement, please initiate the PA process to help your patient save on future NUVIGIL prescriptions If you have questions regarding prior authorization or need forms to assist your patient initiate the prior authorization process, please go to CoverMyMeds.com for assistance PATIENTS WITHOUT INSURANCE COVERAGE FOR NUVIGIL Submit a primary claim to AlphaScrip using Other Coverage Code: 00 or 01 BIN: 610600 PCN: AS Group and ID numbers: located on the card For assistance or questions regarding pharmacy billing, please contact the AlphaScrip Pharmacy Help Desk at 1-877-274-3244. The correct Other Coverage Code is required (see below). Editing the Other Coverage Code may be necessary. 03:...
Words: 935 - Pages: 4
...Teva Strategy Overview February 21, 2008 Forward-Looking Statements TODAY S PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS, WHICH EXPRESS THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT. SUCH STATEMENTS INVOLVE A NUMBER OF KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES THAT COULD CAUSE TEVA'S FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS TO DIFFER SIGNIFICANTLY FROM THE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARDLOOKING STATEMENTS. IMPORTANT FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE RISKS RELATING TO: TEVA'S ABILITY TO ACCURATELY PREDICT FUTURE MARKET CONDITIONS, TEVA'S ABILITY TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE ADDITIONAL PHARMACEUTICAL PRODUCTS, THE INTRODUCTION OF COMPETING GENERIC EQUIVALENTS, THE EXTENT TO WHICH TEVA MAY OBTAIN U.S. MARKET EXCLUSIVITY FOR CERTAIN OF ITS NEW GENERIC PRODUCTS AND REGULATORY CHANGES THAT MAY PREVENT TEVA FROM UTILIZING EXCLUSIVITY PERIODS, COMPETITION FROM BRAND-NAME COMPANIES THAT ARE UNDER INCREASED PRESSURE TO COUNTER GENERIC PRODUCTS, OR COMPETITORS THAT SEEK TO DELAY THE INTRODUCTION OF GENERIC PRODUCTS, POTENTIAL LIABILITY FOR SALES OF GENERIC PRODUCTS PRIOR TO A FINAL RESOLUTION OF OUTSTANDING PATENT LITIGATION, INCLUDING THAT RELATING TO THE GENERIC VERSIONS OF ALLEGRA , NEURONTIN , LOTREL , FAMVIR , AND PROTONIX , THE IMPACT OF CONSOLIDATION OF OUR DISTRIBUTORS AND CUSTOMERS, THE EFFECTS OF COMPETITION ON OUR INNOVATIVE PRODUCTS, ESPECIALLY COPAXONE SALES, THE IMPACT...
Words: 7679 - Pages: 31
...The global pharmaceutical industry has enjoyed steady growth in recent years, despite a global economic downturn. But with patent expiries, stricter regulations, and U.S. healthcare reforms, the pharmaceutical industry is increasingly under pressure to maintain its steady revenue flow. With the patent cliff looming through 2014, many pharmaceutical companies are restructuring to reestablish their industry dominance. They are reinventing themselves through mergers and acquisitions, or are signing licensing deals in order to survive. Real Publishing presents a study of key pharma industry trends. This report offers an analysis of the impact of those trends, and reforms and regulations, particularly in the U.S. and the EU. Key Trends Explored: - Generic drug manufacturers are gearing up to take advantage of the opportunities presented by the many patent expiries - What trends are impacting the leading generic drug manufacturers such as Teva, Sandoz, and others - What government regulations and policies will effect pharma company bottomlines in 2012 and beyond? - How are pharma companies using mergers and acquisitions to maintain a competitive edge? - What is the state of the current global pharmaceutical industry and where is it growing? - Pharmerging countries contribute approximately half of growth, with China as third-largest market Global Pharma Industry Trends Examined: - Challenge of Patent Expiries - Challenges Facing the Generic...
Words: 354 - Pages: 2
...Project Presentation on Dr Reddy’s Laboratories Group 4: Abhishek Aggrawal Anik Bairagi Nishant Sawan Kumar Varun Saini 1 0911074 0911079 0911109 0911127 0911138 Global Pharmaceutical Market - Overview The increasing generics share and shift of the industry towards emerging markets is causing margin pressure on global pharma players and forcing them to invest in these new markets Global Pharmaceutical Market The pharmaceutical market was $ 820Bn in Other Patented 86% 83% 81% 79% 2009, growing at a CAGR of 9% over 200309 Generics is growing at double the rate of the Generics 2004 2006 2008 2010E total industry (18% CAGR), while Patented drugs market is growing at 7% India 1% Geographical Market Share Middle Africa 1% East 1% CIS 2% Others 12% US 42% Top 10 countries account for 73% of sales US accounts for 42% of the world sales While the US sales are growing at only 1-2% CAGR, growth in emerging markets is over 10% Latin America 6% South East and East Asia 6% EU 29% Source: Centrum Research Report on Pharma Industry 2009; 2 Key Growth Drivers for Global Pharmaceutical Market 1 Sluggish Growth in Mature Markets Economic slowdown leading to reduced healthcare spending Top brands’ patent expiries and very few new product launches Decentralization of government healthcare budgets. High healthcare expenditure by government 2 Faster Growth in Emerging Markets Broader public and private...
Words: 3256 - Pages: 14
...investment and declining return in R&D indicates a potential problem of the business model. My proposal is to develop more products and revenue streams through R&D strategies rather than raise prices at the expense of our customers. Right pricing strategy and efficient R&D will bring remarkable benefits to Valeant. Current Pricing Strategy of Valeant In the article “Things to Know about Valeant Pharmaceuticals” from Wall street Journal, Rockoff (2015) argues that practices of lowering R&D spending and adding high-revenue drug assets through aggressive deal making reduced its tax rate and aroused concerns from investors. According to Citron Research (2015), Valeant increased prices of two main heart drugs: Isuprel and Nitropress by 525% and 212% respectively, which exceeded the U.S healthcare industry standard of 6-8%. Valeant’s extreme price tactic is only to beat Wall Street earning estimation and boost its stock price. The research also points out that CEO’s interpretation of price hikes, “Organic Growth of Valeant”, appears to be unreliable. In pharmaceutical industry, increase in prices is essential. However, Valeant’s strategy exceeds the limits of entire healthcare system. In the book, “Pricing for Profit”, Hill (2013) suggests that one method to grow a business is to increase the prices and at the same time satisfy the existing customers. He claims extreme pricing strategy might lead customers to switch to competitors. Therefore, Valeant should use appropriate...
Words: 643 - Pages: 3
...may be injected with an analgesic drug.Propofol in the blood plasma is highly protein bound (97-99%) by serum albumin and hemoglobin. The onset of action is usually rapid and unconsciousness can be induced within 15-40sec of administration on average. This is mostly due to the molecules large volumes of distribution and fast distribution from plasma to CNS. Propofol induces hypnosis by significantly increasing the activity of GABAA (β3, β2) receptors and consequently decreasing neuronal activity. Induction of GABAA β3 receptors is theorized to lead to immobility, respiratory depression and hypnosis while GABAA β2 induction leads to hypnosis, sedation, hypothermia and Cardiac Depression. Along with its fast onset of action Propofol‘s pharmaceutical effects are quickly terminated if the i.v is stopped. The Quick Termination of therapeutic effects is due to decreased blood plasma concentration caused by redistribution of propofol from the CNS to other tissues and high metabolic clearance of the molecule. This leads to rapid recovery from sedation and quicker mobilization of patients. The Metabolism of Propofol by phase I and II hepatic enzymes produces an inactive form for hepatic clearance. Deactivated propofol molecules are mainly eliminated through kidney excretion into nephron tubules. The pharmacokinetics of propofol is not affected by gender or chronic hepatic cirrhosis, but it is affected by age and weight. With increasing Age, the dose needed to achieve anaesthetic effects...
Words: 653 - Pages: 3
...The Pharmaceutical industry has played a large role in American business, society and culture for many years. On March 23, 2010, President Obama signed legislation to approve the Affordable Care Act which overhauls and re-establishes America’s healthcare system. Obama’s reform seeks to provide insurance to more than 30 million Americans who have do not have insurance or were previously denied coverage. This reform will provide opportunities for many industries but specifically, the pharmaceutical industry will see much growth. However, one must look at the effect on brand-name and generic drug manufacturers individually to fully understand the ramifications. Overall, healthcare reform is a large growth opportunity for the pharmaceutical industry and research shows a great deal of support for the legislation. In 2009, pharmaceutical interests spent $188 million lobbying for this healthcare reform and are projected to see a $30 billion net gain over the next 10 years. With the help of the Affordable Care Act, pharmaceutical companies have an opportunity to expand their customer base by over 30 million people but the ones paying for the prescriptions will begin to change from healthcare providers and patients to insurers and managed programs (insurance companies and government programs). Due to this change, the payers will become more cost-conscious in order to sustain continued affordability, thereby relying more on generic drugs than before. The pharmaceutical industry...
Words: 977 - Pages: 4
...Decisions………………………………………………5-7 Possible Future Scenarios…………………………………………………………...7-8 Recommendations for Changes in Culture, Leadership, and/or Structure…………..8-9 Summary/Conclusions………………………………………………………………...9 Reference…………………………………………………………………………10-11 Introduction/Overview To start a company, a person or group of people must realize that it is a bumpy ride from the beginning, and that only those who are prepare enough will succeed. They have to follow multiple rigorous steps and come up with innovative strategies to prove that they have what it takes to be successful in the business. Pfizer Inc. is a company that has proven itself throughout time. They are the world’s largest research based pharmaceutical company and were also recognized by Fortune magazine as the world’s largest pharmaceutical company by profit and second largest by revenue, only next to Johnson and Johnson (Fortune, 2013). Pfizer Inc. have evolve throughout the years along with science and have been responsible for the discovery and marketing of some of the world’s most innovative drugs like, Lipitor (use to decrease cholesterol), Lyrica (use for treatment of fibromyalgia), Zithromax (a renown antibiotic), and many others. Although they focus mainly on human drugs, they also produce animal and consumer healthcare products. The company have apply their science and global resources to help and make a positive impact in the quality of life and health of millions of people and animals around the world. To prove...
Words: 2350 - Pages: 10
...Products Liability Research Paper Select a company that has been the subject of a product liability lawsuit in the last ten (10) years. The Plaintiffs vs. Bayer Pharmaceuticals, the German manufacturer of the birth controls Yaz and Yasmin has landed themselves in hot water and is headed to the courts. Bayer Pharmaceuticals net worth is over a billion dollars and is still climbing. The use of the birth controls Yaz and Yasmin has sparked a lot of attention with claims of a number of dangerous side effects. This case has become very popular, with over 11,300 claims pending and the possibility of more to come, Bayer is expected to pay out about $110 Million in the Yaz case in an attempt to avoid being tried before a jury but that is only the beginning of a long list of active claims. The use of these birth controls are causing an increased number of blood clots in women as well as complications of blood disorders, problems of the heart, strokes, and in some cases even death. www.drugwatch.com the problem appears to be stemming from drospirenone (a progestin) that is found in the birth control pills. In the case of Shannon Landry of Louisiana she filed a complaint with the U.S. district Court for the Southern District of Illinois. In 2000 Landry began taking Yaz and continued until 2010, and shortly thereafter she began having severe side effects. She was later diagnosed with a gallbladder disease called biliary dyskinesia that resulted in surgery to have her gallbladder removed...
Words: 2128 - Pages: 9
...DECEMBER 21, 2012 CORPORATES RATING METHODOLOGY Global Pharmaceutical Industry Summary This rating methodology explains Moody’s approach to assessing credit risk for companies in the pharmaceutical industry globally. This document is intended to provide general guidance that helps companies, investors, and other interested market participants understand how key qualitative and quantitative risk characteristics are likely to affect rating outcomes for companies in the pharmaceutical industry. This document does not include an exhaustive treatment of all factors that are reflected in Moody’s ratings but should enable the reader to understand the qualitative considerations and financial information and ratios that are usually most important for ratings in this sector. This rating methodology replaces 1 the Global Pharmaceutical Industry Methodology published in October 2009. While reflecting many of the same core principles as the 2009 document, this update provides a more transparent presentation of the rating considerations that are usually most important for companies in this sector and incorporates refinements in our analysis that better reflect key credit fundamentals of the industry. No rating changes will result from publication of this rating methodology. This report includes a detailed rating grid and illustrative mapping examples that compare historical performance on factors in the grid to ratings of companies covered by this methodology. The purpose of the...
Words: 13613 - Pages: 55
